Skip to main content

Table 6 Impact of “breast milk antibiotic residues” and “any history of maternal antibiotic usage during early postpartum period” on the maternal BMI change after birth and infant WAZ and HCZ values on admission, multivariate analysis

From: Unexpected drug residuals in human milk in Ankara, capital of Turkey

Breast milk residue Maternal antibiotic usage during postpartum period Overall P for residue P for maternal self-use Interaction between residue and self-use
  Absence Presence
Maternal BMI change after birtha
 Polymyxin −2.53 ± 0.40 −0.15 ± 0.48 −1.34 ± 0.30 0.764 0.004 0.962
 Polymyxin + −2.81 ± 1.08 −0.36 ± 1.09 −1.59 ± 0.77    
Overall   −2.67 ± 0.57 −0.26 ± 0.59     
Infant’s WAZb
 Polymyxin −0.20 ± 0.15 0.18 ± 0.17 −0.01 ± 0.11 0.525 0.176 0.920
 Polymyxin + −0.42 ± 0.39 0.02 ± 0.39 −0.20 ± 0.27    
 Overall   −0.31 ± 0.21 0.10 ± 0.21     
Maternal BMI change (kg/m2) after birtha
 Aminoglycoside −2.72 ± 0.45 −0.39 ± 0.53 −1.55 ± 0.34 0.364 < 0.001 0.889
 Aminoglycoside + −2.23 ± 0.67 0.27 ± 0.79 −0.98 ± 0.52    
 Overall   −2.47 ± 0.40 −0.06 ± 0.47     
Infant’s WAZb
 Aminoglycoside −0.17 ± 0.16 0.17 ± 0.20 0.00 ± 0.13 0.585 0.067 0.751
 Aminoglycoside + −0.36 ± 0.25 0.12 ± 0.25 −0.12 ± 0.18    
 Overall   −0.26 ± 0.15 0.15 ± 0.16     
  1. Values were mean ± standart error of mean
  2. a Analysed with general linear models adjusted for maternal age, smoke exposure, gestational length, birth type, maternal BMI at birth, maternal disease, breastfeeding type, infant age
  3. b Exclusive breast fed infants were enrolled and analysed with general linear models adjusted for maternal age, maternal disease, smoke exposure, gestational length, birth type, infant’s WAZ at birth, infant age